# Competing subclones and fitness diversity shape tumor evolution across cancer types

**Authors:** Hai Chen, Jingmin Shu, Rekha Mudappathi, Elaine Li, Panwen Wang, Leif Bergsagel, Ping Yang, Zhifu Sun, Logan Zhao, Changxin Shi, Jeffrey P Townsend, Carlo Maley, Li Liu

PMC · DOI: 10.1093/bioinformatics/btag127 · 2026-03-13

## TL;DR

This paper introduces TEATIME, a computational tool that infers tumor evolution from single-timepoint data, revealing how competing subclones and fitness diversity shape cancer progression.

## Contribution

TEATIME is a novel framework that models tumor evolution using single-timepoint data and introduces the concept of fitness diversity to quantify intratumor heterogeneity.

## Key findings

- TEATIME estimates mutation rates, subclone emergence timing, and fitness diversity from bulk sequencing data.
- Immune-hot microenvironments constrain subclonal expansion and reduce fitness diversity.
- Early driver mutations in ancestral clones influence the fitness landscape and subclone selection.

## Abstract

Intratumor heterogeneity arises from ongoing somatic evolution and complicates cancer diagnosis, prognosis, and treatment. Reconstructing evolutionary dynamics typically requires spatiotemporal samples, which are often unavailable in clinical settings. Computational approaches that can infer tumor evolutionary history from single-timepoint bulk sequencing data remain limited.

We present estimating evolutionary events through single-timepoint sequencing (TEATIME), a novel computational framework that models tumors as mixtures of two competing cell populations: an ancestral clone with baseline fitness and a derived subclone with elevated fitness. Using cross-sectional bulk sequencing data, TEATIME estimates mutation rates, timing of subclone emergence, relative fitness, and number of generations of growth. To quantify intratumor fitness asymmetries, we introduce a novel metric—fitness diversity—which captures the imbalance between competing cell populations and serves as a measure of functional intratumor heterogeneity. Applying TEATIME to 33 tumor types from The Cancer Genome Atlas, we revealed divergent as well as convergent evolutionary patterns. Notably, we found that immune-hot microenvironments constraint subclonal expansion and limit fitness diversity. Moreover, we detected temporal dependencies in mutation acquisition, where early driver mutations in ancestral clones epistatically shape the fitness landscape, predisposing specific subclones to selective advantages. These findings underscore the importance of intratumor competition and tumor-microenvironment interactions in shaping evolutionary trajectories, driving intratumor heterogeneity. Lastly, we demonstrate that TEATIME-derived evolutionary parameters and fitness diversity offer novel prognostic insights across multiple cancer types.

R implementation of TEATIME is available on GitHub (https://github.com/liliulab/TEATIME) and Zenodo (https://zenodo.org/records/17422174).

## Full-text entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, MMRN1 (multimerin 1) [NCBI Gene 22915] {aka ECM, EMILIN4, GPIa*, MMRN}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, IDH1 (isocitrate dehydrogenase (NADP(+)) 1) [NCBI Gene 3417] {aka HEL-216, HEL-S-26, IDCD, IDH, IDP, IDPC}, FBXW7 (F-box and WD repeat domain containing 7) [NCBI Gene 55294] {aka AGO, CDC4, DEDHIL, FBW6, FBW7, FBX30}, RAP1A (RAP1A, member of RAS oncogene family) [NCBI Gene 5906] {aka C21KG, G-22K, KREV-1, KREV1, RAP1, SMGP21}, NTHL1 (nth like DNA glycosylase 1) [NCBI Gene 4913] {aka FAP3, NTH1, OCTS3, hNTH1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}
- **Diseases:** endocervical adenocarcinoma (MESH:D000230), UCEC (MESH:D016889), uterine tumors (MESH:D014594), AML (MESH:D015470), metastases (MESH:D009362), lung cancers (MESH:D008175), colorectal carcinogenesis (MESH:D063646), ESCA (MESH:D004938), tumorigenic (MESH:D002471), bladder urothelial carcinoma (MESH:D001749), colorectal cancer (MESH:D015179), LUAD (MESH:D000077192), GBM (MESH:D005910), glioblastoma multiforme (MESH:D005909), Pan-cancer (MESH:D009369), LGG (MESH:D008228), Breast Cancer (MESH:D001943), COAD (MESH:D003110), brain tumors (MESH:D001932), LUSC (MESH:D002294), precancerous (MESH:D011230), inflammation (MESH:D007249)
- **Chemicals:** 5-mC (-), 5-methylcytosine (MESH:D044503)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025073/full.md

---
Source: https://tomesphere.com/paper/PMC13025073